Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.52 |
| ▸ | FKBP5 | Q13451 | 3/20 | 0.52 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15048986 | 1.00 | FKBP1A (0.52) | FKBP1AFKBP5FKBP4KDM4EPARP15 | |
| SCHEMBL15049048 | 0.85 | KDM4E (0.55) | FKBP1AKDM4EMEN1KMT2AEPHX1 | |
| SCHEMBL15049047 | 0.85 | KDM4E (0.55) | FKBP1AKDM4EMEN1KMT2AEPHX1 | |
| SCHEMBL18120730 | 0.84 | KMT2A (0.46) | FKBP1AMEN1KMT2A | |
| SCHEMBL22861528 | 0.77 | FKBP1A (0.49) | FKBP1AKDM4EMEN1KMT2A | |
| SCHEMBL21241611 | 0.77 | FKBP1A (0.49) | FKBP1AKDM4EMEN1KMT2A | |
| SCHEMBL11449248 | 0.76 | CHRNB4 (0.50) | MEN1KMT2ACHRNB4CHRNA3HIF1A | |
| SCHEMBL19337325 | 0.76 | FKBP1A (0.66) | FKBP1AFKBP5FKBP4KDM4EPARP15 | |
| SCHEMBL21241612 | 0.75 | FKBP1A (0.53) | FKBP1AKDM4E | |
| SCHEMBL22861533 | 0.75 | FKBP1A (0.53) | FKBP1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-2877470-B1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2877470-B1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9371322-B2 | Bicyclic aza-amides for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20150183786-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESSELSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-07-02 | — | — | US | disclosed |
| EP-2877470-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-06-03 | — | — | EP | disclosed |
| EP-2794566-A1 | PIPECOLATE-DIKETOAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014015993-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015993-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-30 | — | — | WO | disclosed |
| EP-2690102-A1 | Bicyclic aza-amides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690102-A1 | Bicyclic aza-amides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-29 | — | — | EP | disclosed |
| WO-2013064703-A9 | FKBP SUBTYPE-SPECIFIC RAPAMYCIN ANALOGUE FOR USE IN TREATMENT OF DISEASES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013091900-A1 | PIPECOLATE-DIKETOAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-06-27 | — | — | WO | disclosed |
| EP-2607352-A1 | Pipecolate-diketoamides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-06-26 | — | — | EP | disclosed |
| WO-2013064703-A2 | FKBP SUBTYPE-SPECIFIC RAPAMYCIN ANALOGUE FOR USE IN TREATMENT OF DISEASES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183786-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | BDNF, MAOA, HDAC10 | FKBP1A 98/4885FKBP5 61/4885FKBP4 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.